When was SoftOx founded?

SoftOx was founded in 2012 and raised its 1st funding round 6 years after it was founded.

Where is SoftOx located?

SoftOx is headquartered in Oslo, Norway. It is registered at Martin Linges vei 25, 1364, FORNEBU.

How many employees does SoftOx have?

As of Aug 31, 2026, the latest employee count at SoftOx is 13.

Is SoftOx a funded company?

SoftOx is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 01, 2018.

When was the latest funding round of SoftOx?

SoftOx's latest funding was a $***** Post IPO round on Oct 11, 2022, with participation from 0 investor.

Where does SoftOx rank among its competitors?

SoftOx ranks 140th amongst 422 active competitors, of which 120 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Vedanta Biosciences, which secured $60M in Aug, 2026.

Who are the top competitors of SoftOx?

SoftOx's top competitors include Spero Therapeutics, Locus Biosciences and LimmaTech Biologics. Among them, Vedanta Biosciences secured the most recent funding round in August, 2026.

SoftOx - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of topical antiseptic products for chronic wounds. Its patented technology uses acetic acid together with the body’s own disinfector. The product, SoftOx topical antiseptic is the non-toxic, alcohol-free topical antiseptic, that prevents and removes biofilm located beneath a wound surface.

Website: soft-ox.com
Social
Email ID: *****@soft-ox.com
Phone Number: +47 **********
Registered Address: Martin Linges vei 25, 1364, FORNEBU

Key Metrics

Founded Year

2012

Location

Oslo, Norway

Stage

Public

Latest Funding Round

Post IPO, Oct 11, 2022, $*****

Investors

EIC Fund & 1 more

Ranked

140^th among 422 active competitors

Employee Count

13 as on Aug 31, 2026

Similar Companies

Spero Therapeutics & 509 more

Exit Details

Public

View SoftOx's full profile

SoftOx is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
SOFTOX SOLUTIONS AS CIN: 998516390 , Norway, Active	May 07, 2012	-	6 (As on Dec 31, 2022)
SoftOx Solutions AS CIN: 998516390 , Norway, Active	Aug 04, 2012	-	21 (As on Dec 31, 2021)

SoftOx got listed on May 14, 2021.

Click here to take a look at SoftOx's IPO in detail

SoftOx has raised funding over 3 rounds. Its first funding round was on Jun 01, 2018. SoftOx has 2 institutional investors.

Here is the list of recent funding rounds of SoftOx:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 11, 2022	3950586	Post IPO	6583031	5804463	2571423	2678620
Nov 30, 2018	8151127	Grant (prize money)	8213565	5852502	6748625	EIC Fund
Jun 01, 2018	3184223	Grant (prize money)	5182524	6248620	2329474	Europa

Access funding benchmarks and valuations. Sign up today!

View details of SoftOx's funding rounds and investors

SoftOx's employee count trend

SoftOx has 13 employees as of Aug 26. Here is SoftOx's employee count trend over the years:

Uncover SoftOx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SoftOx include Spero Therapeutics, Locus Biosciences and LimmaTech Biologics. Here is the list of Top 10 competitors of SoftOx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Spero Therapeutics 2013, Cambridge (United States), Public	Developer of therapeutics for drug-resistant bacterial infections	$115M	Atlas Venture, Partners Health Care Innovation ... & 16 others	69/100
2nd	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Illumina & 13 others	64/100
3rd	LimmaTech Biologics 2015, Schlieren (Switzerland), Acquired	Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques	$40M	REPAIR Impact Fund, Tenmile & 4 others	63/100
4th	SolasCure 2017, Cambridge (United Kingdom), Series B	Developer of biologic therapies for the treatment of chronic wounds	$34.1M	Seneca, Tricor Group & 66 others	62/100
5th	Paratek Pharma 1996, Boston (United States), Acquired	Developer of therapeutics for antimicrobial resistant infections	$96.5M	Phase4 Partners, Athyrium Capital Management ... & 25 others	61/100
6th	Everest Medicines 2017, New York City (United States), Public	Developer of drugs for the treatment of cancer	$313M	RA Capital Management, Hillhouse & 12 others	61/100
7th	Bioversys 2008, Basel (Switzerland), Public	Developer of therapeutics for Antimicrobial Resistance	$62.5M	AMR Action Fund, Wellcome Trust & 10 others	61/100
8th	MicuRx Pharmaceuticals 2007, Foster City (United States), Series E	Develops antibiotics against multidrug-resistant (MDR) superbug infections	$272M	BioVeda China Fund, Legend Capital & 9 others	60/100
9th	SanuWave 2005, Alpharetta (United States), Public	Developer of Noninvasive devices, and biologics for wound healing	$1.43M	CIT, Kingswood Capital Markets	60/100
10th	Vedanta Biosciences 2010, Cambridge (United States), Series E	Developer of therapeutics to treat infectious diseases	$410M	Invesco, Seventure Partners & 40 others	59/100
140th	SoftOx 2012, Oslo (Norway), Public	Developer of topical antiseptic products for chronic wounds	-	EIC Fund, Europa	35/100